Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.